4D Molecular Therapeutics, Inc. (FDMT)

Several events have influenced FDMT's stock price in the past six months, including Q2 and Q3 2025 earnings reports, a company update outlining anticipated development milestones for 2026, and positive interim Phase 1 data for 4D-710 in Cystic Fibrosis. The stock experienced a fall after early-stage trial data for cystic fibrosis therapy was released, and Kristian Humer was appointed as the new CFO. The stock price decreased by 31.32% over the last month as of January 9, 2026, and fell in 7 of the last 10 days, down by 5.9% as of January 12, 2026. A buy signal was issued from a pivot bottom point on January 6, 2026, leading to a 4.31% rise since then. Insiders sold $87,277.00 in company stock with no insider buying in the past three months.

Specific information regarding the demand seasonality for 4D Molecular Therapeutics, Inc.'s products and services is not publicly available in the provided search results.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing genetic medicines for serious unmet medical conditions in ophthalmology, pulmonology, and cardiology, operating within the Healthcare sector and Biotechnology industry. The company utilizes its Therapeutic Vector Evolution platform to develop targeted AAV vectors, with product candidates including 4D-150, 4D-125, 4D-110, and 4D-175 for ophthalmology; 4D-710 and 4D-725 for pulmonology; and 4D-310 for cardiology.

4D Molecular Therapeutics, Inc. is headquartered in Emeryville, California, and develops adeno-associated virus vectors from its synthetic vector discovery platform in both the Netherlands and the United States.

4D Molecular Therapeutics has maintained a relatively favorable brand reputation in the media, with an average media sentiment score of 0.45. The company has a consensus rating of "Moderate Buy" and an average price target indicating significant upside potential. Positive interim Phase 1 data for its cystic fibrosis therapy and various analyst recommendations have contributed to its public perception.

4D Molecular Therapeutics, Inc. has a significant concentration of institutional ownership, with approximately 49% to 99.3% of the stock held by institutional investors, including BVF Inc/il, Ra Capital Management, L.p., Goldman Sachs Group Inc, BlackRock, Inc., Vanguard Group Inc, Novo Holdings A/S, Janus Henderson Group Plc, Federated Hermes, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Millennium Management Llc. Insiders hold about 2.12% to 9.6% of the stock, with CEO David Kirn holding a 3.0% stake. The general public holds approximately 23% to 49.06% ownership.